KRAS and hepatocellular carcinoma: A 99-aa micropeptide named KRASIM encoded by lncRNA NCBP2-AS2, discovered through ribosome profiling and notably differently expressed in normal hepatocytes and hepatocellular carcinoma (HCC) cells, has been shown to interact with KRAS and inhibit ERK signaling in HCC cells.